Staphylococcus AureusPhase 4NCT03140423
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
A Phase 4 study testing Arm 1. Routine Care (Mupirocin/CHG) and Arm 2. Iodophor/CHG Decolonization in people with Staphylococcus Aureus, run by Harvard Pilgrim Health Care at 137 sites in United States.
Trial summary
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens: Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing; Arm 2 Intervention: ICU nasal decolonization… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Staphylococcus Aureus
- What is being tested?
- Arm 1. Routine Care (Mupirocin/CHG) and Arm 2. Iodophor/CHG Decolonization
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 353,323 participants
- Where
- 137 sitesUnited States
- Study dates
- 1 May 2017to 6 Nov 2023
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;
- Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs
- All patients within adult ICUs are included, including rare patients <18 years and >=12 years.
Who cannot join
- Exclusion criteria includes ICUs with an average length of stay of less than 2 days;
- HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.
Trial locations and contacts
137 sites in 1 country.
137 sites in 1 country
United States137 sites
Rapides Regional Medical Center
Alexandria, Louisiana, 71301
Medical Center of Arlington
Arlington, Texas, 76015
JFK Medical Center
Atlantis, Florida, 33462
Doctor's Hospital Augusta
Augusta, Georgia, 30909
The Medical Center of Aurora
Aurora, Colorado, 80012
South Austin Hospital
Austin, Texas, 78704
North Austin Medical Center
Austin, Texas, 78758
Aventura Hospital
Aventura, Florida, 33180
Belton Regional Medical Center
Belton, Missouri, 64012
LewisGale Hospital - Montgomery
Blacksburg, Virginia, 24060
Lakeview Hospital
Bountiful, Utah, 84010
Greenview Regional Hospital
Bowling Green, Kentucky, 42104
Blake Medical Center
Bradenton, Florida, 34209
Brandon Regional
Brandon, Florida, 33511
Oak Hill Hospital
Brooksville, Florida, 34613
Valley Regional Medical Center
Brownsville, Texas, 78526
West Valley Medical Center
Caldwell, Idaho, 83605
Cartersville Medical Center
Cartersville, Georgia, 30120
Trident Regional Medical Center
Charleston, South Carolina, 29406
Parkridge Medical Center
Chattanooga, Tennessee, 37404
Parkridge East Hospital
Chattanooga, Tennessee, 37412
Conroe Regional Medical Center
Conroe, Texas, 77304
Corpus Christi Medical Center - Doctor's
Corpus Christi, Texas, 78411
Corpus Christi Medical Center - The Heart Hospital
Corpus Christi, Texas, 78412
Lakeview Regional Medical Center
Covington, Louisiana, 70433
Medical City Dallas Hospital
Dallas, Texas, 75230
Denton Regional Medical Center
Denton, Texas, 76210
Swedish Medical Center
Denver, Colorado, 80113
Sky Ridge Medical Center
Denver, Colorado, 80124
Presbyterian St. Luke's Medical Center
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
Parkland Medical Center
Derry, New Hampshire, 03038
Fairview Park
Dublin, Georgia, 31021
Las Palmas Medical Center
El Paso, Texas, 79902
Del Sol Medical Center
El Paso, Texas, 79925
Englewood Community Hospital
Englewood, Florida, 34223
Fort Walton Medical Center
Fort Walton Beach, Florida, 32547
Plaza Medical Center of Fort Worth
Fort Worth, Texas, 76104
Spotsylvania Regional Medical Center
Fredericksburg, Pennsylvania, 22408
Lawnwood Regional Medical Center
Ft. Pierce, Florida, 34950
North Florida Regional Medical Center
Gainesville, Florida, 32605
Garden Park Medical Center
Gulfport, Mississippi, 39503
Hendersonville Medical Center
Hendersonville, Tennessee, 37075
Summit Medical Center
Hermitage, Tennessee, 37076
John Randolph Medical Center
Hopewell, Virginia, 23860
East Houston Regional Medical Center
Houston, Texas, 77015
West Houston Medical Center
Houston, Texas, 77082
Regional Medical Center Bayonet Point
Hudson, Florida, 34667
Eastern Idaho Regional
Idaho Falls, Idaho, 83404
Centerpoint Medical Center
Independence, Missouri, 64057
Las Colinas Medical Center
Irving, Texas, 75039
Memorial Hospital Jacksonville
Jacksonville, Florida, 32216
Research Medical Center
Kansas City, Missouri, 64132
Kingwood Medical Center
Kingwood, Texas, 77339
Osceola Regional Medical Center
Kissimmee, Florida, 34741
Poinciana Medical Center
Kissimmee, Florida, 34758
Lake City Medical Center
Lake City, Florida, 32055
Largo Medical Center
Largo, Florida, 33770
Sunrise Hospital & Medical Center
Las Vegas, Nevada, 89109
Mountainview Hospital - Vegas
Las Vegas, Nevada, 89128
Southern Hills Hospital - Vegas
Las Vegas, Nevada, 89148
Lee's Summit Medical Center
Lee's Summit, Missouri, 64063
Medical Center of Lewisville
Lewisville, Texas, 75057
LewisGale Hospital - Alleghany
Low Moor, Virginia, 24457
Palms West Hospital
Loxahatchee Groves, Florida, 33470
Coliseum Medical Centers - Main
Macon, Georgia, 31217
Coliseum Medical Centers - Northside
Macon, Georgia, 31217
Northwest Medical Center
Margate, Florida, 33063
Rio Grande Regional Hospital
McAllen, Texas, 78503
Medical Center of McKinney
McKinney, Texas, 75069
Mercy Hospital
Miami, Florida, 33133
Kendall Regional Medical Center
Miami, Florida, 33175
Grand Strand Regional Medical Center
Myrtle Beach, South Carolina, 29572
Stonecrest Medical Center
Nashville, Tennessee, 37167
Centennial Medical Center
Nashville, Tennessee, 37203
Skyline Medical Center
Nashville, Tennessee, 37207
Southern Hills Medical Center
Nashville, Tennessee, 37211
Tulane University Hospital & Clinic
New Orleans, Louisiana, 70112
Twin Cities Hospital
Niceville, Florida, 32578
North Hills Hospital
North Richland Hills, Texas, 76180
Ocala Regional Medical Center
Ocala, Florida, 34471
West Marion Community Hospital
Ocala, Florida, 34474
Ogden Regional Medical Center
Ogden, Utah, 84405
Raulerson Hospital
Okeechobee, Florida, 34972
Orange Park Medical Center
Orange Park, Florida, 32073
Timpanogos Regional Medical Center
Orem, Utah, 84057
Menorah Medical Center
Overland Park, Kansas, 66209
Overland Park Regional Medical Center
Overland Park, Kansas, 66215
Gulf Coast Medical Center
Panama City, Florida, 32405
Bayshore Medical Center
Pasadena, Texas, 77504
Mountain View Hospital - Utah
Payson, Utah, 84651
West Florida Hospital
Pensacola, Florida, 32514
Medical Center of Plano
Plano, Texas, 75075
Plantation General Hospital
Plantation, Florida, 33317
Westside Regional Medical Center
Plantation, Florida, 33324
Fawcett Memorial Hospital
Port Charlotte, Florida, 33952
St. Lucie Medical Center
Port Saint Lucie, Florida, 34952
Portsmouth Regional Hospital
Portsmouth, New Hampshire, 03801
LewisGale Hospital - Pulaski
Pulaski, Virginia, 24301
Reston Hospital
Reston, Virginia, 20190
Henrico Doctors' Hospital - Retreat Campus
Richmond, Virginia, 23220
CJW Medical Center (Chippenham Campus)
Richmond, Virginia, 23225
CJW Medical Center (Johnston Willis Campus)
Richmond, Virginia, 23225
Henrico Doctors' Hospital - Forest Campus
Richmond, Virginia, 23229
Henrico Doctors' Hospital - Parham Campus
Richmond, Virginia, 23294
Riverside Community Hospital
Riverside, California, 92501
Redmond Regional Medical Center
Rome, Georgia, 30165
Round Rock Hospital
Round Rock, Texas, 78681
LewisGale Medical Center
Salem, Virginia, 24153
Metropolitan Methodist Hospital
San Antonio, Texas, 78212
Methodist Hospital
San Antonio, Texas, 78229
Methodist Specialty & Transplant Hospital
San Antonio, Texas, 78229
Methodist Stone Oak Hospital
San Antonio, Texas, 78229
Methodist Texsan Hospital
San Antonio, Texas, 78229
Northeast Methodist Hospital
San Antonio, Texas, 78229
Regional Medical Center of San Jose
San Jose, California, 95116
Good Samaritan Hospital
San Jose, California, 95124
Central Florida Regional Hospital
Sanford, Florida, 32771
Doctor's Hospital Sarasota
Sarasota, Florida, 34233
Eastside Medical Center
Snellville, Georgia, 30078
Northside Hospital
St. Petersburg, Florida, 33709
St. Petersburg General Hospital
St. Petersburg, Florida, 33710
Summerville Medical Center
Summerville, South Carolina, 29485
South Bay Hospital
Sun City Center, Florida, 33573
Capital Regional Medical Center
Tallahassee, Florida, 32308
University Hospital & Medical Center
Tamarac, Florida, 33321
Terre Haute Regional Hospital
Terre Haute, Indiana, 47802
Mainland Medical Center
Texas City, Texas, 77591
North Suburban Medical Center - JV
Thornton, Colorado, 80229
Los Robles Regional Medical Center
Thousand Oaks, California, 91360
Medical Center of Trinity
Trinity, Florida, 34655
Colleton Medical Center
Walterboro, South Carolina, 29488
Clearlake Regional Medical Center
Webster, Texas, 77598
West Hills Hospital & Medical Center
West Hills, California, 91307
JFK Medical Center - North Campus
West Palm Beach, Florida, 33407
Wesley Medical Center
Wichita, Kansas, 67214
Wesley Woodlawn Hospital
Wichita, Kansas, 67220
About this study
Official title: Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens:
Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing; Arm 2 Intervention: ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing Note: that enrolled "subjects" represents 137 individual HCA Hospitals (representing ~235 ICUs) that have been randomized.
- Conditions
- Staphylococcus Aureus
- Being tested
- Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
- Keywords
- MRSA, healthcare-associated infections, mupirocin, iodophor, resistance
- Medical subject headings
- Staphylococcal Infections, Cross Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Arm 1. Routine Care (Mupirocin/CHG)Drug
The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
Arm 2. Iodophor/CHG DecolonizationDrug
The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1: Routine Care (Mupirocin/CHG) | Active comparator | ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing Receives: Drug: Arm 1. Routine Care (Mupirocin/CHG) |
| Arm 2: Iodophor/CHG Decolonization | Active comparator | ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing Receives: Drug: Arm 2. Iodophor/CHG Decolonization |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures
Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-susceptible Staphylococcus aureus (MSSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge. NOTE: this outcome is intended for the primary manuscript.
Measured: 18-month intervention
Secondary outcomes (2)
Number of Participants With ICU Attributable MRSA Clinical Cultures
Methicillin-resistant Staphylococcus aureus (MRSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge. NOTE: this outcome is intended for the primary manuscript.
Measured: 18-month intervention
Number of Participants With ICU-attributable Bloodstream Infections
All-cause bloodstream infection attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge.Includes subsets of gram positive (GP), gram negative (GN) and fungal (candida) bloodstream infections, as well as key pathogens such as S. aureus (MRSA and MSSA). NOTE: this outcome is intended for the primary manuscript.
Measured: 18-month intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2017
- Study start1 May 2017
- Primary completion6 Nov 2023
- Study completion6 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Staphylococcus AureusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Non-inferiority cluster randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 353,323 participants (actual)
Sponsor and investigators
- Lead sponsor
- Harvard Pilgrim Health Care
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Corporation of America, University of California, Irvine, University of Massachusetts, Amherst, Rush University, Centers for Disease Control and Prevention
- Responsible party
- Principal investigator, Richard Platt, Harvard Pilgrim Health Care
- Investigators
- Richard Platt, MD, MS, Principal investigator, Harvard Pilgrim Health Care InstituteSusan Huang, MD, MPH, Study director, University of California, Irvine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03140423
- Sponsor's protocol ID
- PH000599A
- Status last verified
- Mar 2025
- First submitted
- 12 Apr 2017
- Last updated
- 30 Mar 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Huang SS, Septimus EJ, Kleinman K, Heim LT, Moody JA, Avery TR, McLean L, Rashid S, Haffenreffer K, Shimelman L, Staub-Juergens W, Spencer-Smith C, Sljivo S, Rosen E, Poland RE, Coady MH, Lee CH, Blanchard EJ, Reddish K, Hayden MK, Weinstein RA, Carver B, Smith K, Hickok J, Lolans K, Khan N, Sturdevant SG, Reddy SC, Jernigan JA, Sands KE, Perlin JB, Platt R. Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial. JAMA. 2023 Oct 10;330(14):1337-1347. doi: 10.1001/jama.2023.17219.
PubMed 37815567
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing
- ClinicalTrials.gov ID
- NCT03140423
- Acronym / sponsor ID
- PH000599A
- Conditions
- Staphylococcus Aureus
- Keywords
- MRSA, healthcare-associated infections, mupirocin, iodophor, resistance
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 353,323 participants (actual)
- Lead sponsor
- Harvard Pilgrim Health CareUniversity, hospital or other
- Collaborators
- Hospital Corporation of America, University of California, Irvine, University of Massachusetts, Amherst, Rush University, Centers for Disease Control and Prevention
- Study start
- 1 May 2017 (actual)
- Primary completion
- 6 Nov 2023 (actual)
- Study completion
- 6 Nov 2023 (actual)
- First posted
- 4 May 2017 (actual)
- Results
- Posted 7 Feb 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens:
Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing; Arm 2 Intervention: ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing Note: that enrolled "subjects" represents 137 individual HCA Hospitals (representing ~235 ICUs) that have been randomized.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Non-inferiority cluster randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Arm 1: Routine Care (Mupirocin/CHG) | Active comparator | Drug: Arm 1. Routine Care (Mupirocin/CHG)ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing |
| Arm 2: Iodophor/CHG Decolonization | Active comparator | Drug: Arm 2. Iodophor/CHG DecolonizationICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;
- Note: Unit of randomization is the hospital, but the participants are hospital adult ICUs
- All patients within adult ICUs are included, including rare patients <18 years and >=12 years.
Key exclusion criteria (2 listed)
- Exclusion criteria includes ICUs with an average length of stay of less than 2 days;
- HCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Arm 1. Routine Care (Mupirocin/CHG)The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths. | Drug | Arm 1: Routine Care (Mupirocin/CHG) |
| Arm 2. Iodophor/CHG DecolonizationThe intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths. | Drug | Arm 2: Iodophor/CHG Decolonization |
Primary outcome
Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures
Time frame: 18-month intervention
Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-susceptible Staphylococcus aureus (MSSA) clinical cultures attributable to participating ICUs. Defined as occurring >2 days into a participating ICU stay through 2 days following ICU discharge. NOTE: this outcome is intended for the primary manuscript.
2 secondary outcomes
Number of Participants With ICU Attributable MRSA Clinical Cultures
Time frame: 18-month intervention
Number of Participants With ICU-attributable Bloodstream Infections
Time frame: 18-month intervention
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 37815567Huang SS, Septimus EJ, Kleinman K, Heim LT, Moody JA, Avery TR, McLean L, Rashid S, Haffenreffer K, Shimelman L, Staub-Juergens W, Spencer-Smith C, Sljivo S, Rosen E, Poland RE, Coady MH, Lee CH, Blanchard EJ, Reddish K, Hayden MK, Weinstein RA, Carver B, Smith K, Hickok J, Lolans K, Khan N, Sturdevant SG, Reddy SC, Jernigan JA, Sands KE, Perlin JB, Platt R. Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial. JAMA. 2023 Oct 10;330(14):1337-1347. doi: 10.1001/jama.2023.17219.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Staphylococcus Aureus
Active, not recruitingPhase 1/2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
Active, not recruitingPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
Staphylococcus Aureus Bloodstream Infection
RecruitingPhase 4
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia
RecruitingPhase 4
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
RecruitingPhase 4
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Platt, MD, MS principal investigator
Harvard Pilgrim Health Care Institute
Susan Huang, MD, MPH study director
University of California, Irvine
137 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Arm 1. Routine Care (Mupirocin/CHG) and Arm 2. Iodophor/CHG Decolonization in people with Staphylococcus Aureus, run by Harvard Pilgrim Health Care at 137 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 137 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Feb 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures (time frame: 18-month intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03140423, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2025; AzTrials last refreshed its copy on 26 Oct 2026.